GPR139抗体—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human lung cancer tissue using P06631(GPR139 Antibody) at dilution 1/50. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human prostate cancer tissue using P06631(GPR139 Antibody) at dilution 1/50. (Original magnification: ×200)    

  
  

GPR139 is a class A G protein-coupled receptor (GPCR) primarily expressed in the central nervous system, particularly in regions like the hypothalamus, striatum, and habenula. It was deorphanized in 2015. with studies identifying L-tryptophan and phenylalanine metabolites (e.g., quinolinic acid) as potential endogenous agonists. GPR139 is implicated in modulating neurophysiological processes such as feeding behavior, locomotor activity, and circadian rhythms, though its precise signaling mechanisms and physiological roles remain under investigation.

Antibodies targeting GPR139 are critical tools for studying its expression, localization, and function. These antibodies, often raised against extracellular or intracellular epitopes, enable techniques like immunohistochemistry, Western blotting, and flow cytometry. Specificity validation via knockout controls is essential due to structural similarities among GPCRs. Research using GPR139 antibodies has revealed its potential involvement in neurological and psychiatric disorders, including schizophrenia, Parkinson’s disease, and depression, positioning it as a therapeutic target. Recent studies also explore its role in metabolic regulation and pain perception. Despite progress, challenges persist in developing antibodies with high affinity and minimal cross-reactivity, underscoring the need for continued refinement to advance both basic research and drug discovery efforts targeting GPR139.